Clifford Chance
The Application of the Anti-Monopoly Law to the Pharmaceutical Sector in China
18 October 2017
In this article, the authors Yong Bai, Counsel, Clifford Chance and Richard Blewett, Partner, Clifford Chance explore the application of China's Anti-Monopoly Law ,in force since 2008, to the Chinese pharmaceutical sector. Competition law issues affecting this industry are technical, complex and varied, and have been a priority in antitrust enforcement to date. While the general assessment of these problems by China's competition authorities greatly mirrors international practice, there are some unique traits that aim to deal with the specific local context. The authors consider and assess these peculiarities.
First published in the China Antitrust Law Journal (Volume 1 / Issue 1 / Summer 2017), a new periodical developed by the China Institute of International Antitrust and Investment together with LexisNexis. [Click here for more information].
Download File
The Application of the Anti-Monopoly Law to the Pharmaceutical Sector in China
